



UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office  
Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

APPLICATION NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
--------------------	-------------	-----------------------	------------------

09/325,019 06/03/99 YOUNG

P PF467

EXAMINER

022195 HM22/1107  
HUMAN GENOME SCIENCES INC  
9410 KEY WEST AVENUE  
ROCKVILLE MD 20850

SPECTOR

ART UNIT

PAPER NUMBER

1647

DATE MAILED:

11/07/01

This is a communication from the examiner in charge of your application.  
COMMISSIONER OF PATENTS AND TRADEMARKS

OFFICE ACTION SUMMARY

☒ Responsive to communication(s) filed on 8/15/01

☐ This action is FINAL.

☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 D.C. 11; 453 O.G. 213.

A shortened statutory period for response to this action is set to expire 3 month(s), or thirty days, whichever is longer, from the mailing date of this communication. Failure to respond within the period for response will cause the application to become abandoned. (35 U.S.C. § 133). Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

Disposition of Claims

☒ Claim(s) 11, 13, 17, 18, 20, 22-105 is/are pending in the application.

Of the above, claim(s) 11, 13, 17, 18, 20, 22, 23, 26-33, 48-50, 52, 54, 67-105 are withdrawn from consideration.

☐ Claim(s) \_\_\_\_\_ is/are allowed.

☒ Claim(s) 24, 25, 34-47, 51, 55-66 is/are rejected.

☐ Claim(s) \_\_\_\_\_ is/are objected to.

☒ Claim(s) 11, 13, 17, 18, 20, 22-105 are subject to restriction or election requirement.

Application Papers

☒ See the attached Notice of Draftsperson's Patent Drawing Review, PTO-948.

☐ The drawing(s) filed on \_\_\_\_\_ is/are objected to by the Examiner.

☐ The proposed drawing correction, filed on \_\_\_\_\_ is ☐ approved ☐ disapproved.

☐ The specification is objected to by the Examiner.

☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. § 119

☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).

☐ All ☐ Some\* ☐ None of the CERTIFIED copies of the priority documents have been

☐ received.

☐ received in Application No. (Series Code/Serial Number) \_\_\_\_\_

☐ received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

\*Certified copies not received: \_\_\_\_\_

☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e).

Attachment(s)

☒ Notice of Reference Cited, PTO-892

☒ Information Disclosure Statement(s), PTO-1449, Paper No(s) 8+13

☐ Interview Summary, PTO-413

☒ Notice of Draftsperson's Patent Drawing Review, PTO-948

☐ Notice of Informal Patent Application, PTO-152

--SEE OFFICE ACTION ON THE FOLLOWING PAGES--

**Part III: Detailed Office Action**

**Restriction Requirement:**

Applicant's election with traverse of the sequence of SEQ ID NO: residues 1-335 in Paper No. 12, filed 8/15/01 is acknowledged. The traversal is on the ground(s) that (a) the Examiner has not shown that examination of the entire invention would present a serious search burden, (b) that the Examiner has not disclosed any statutory or regulatory basis for requiring the election of an individual sequence within the previously elected Group I, (c) that the current restriction represents a restriction within a Markush group, and that said Markush group has members that are sufficiently few in number and very closely related, so that a search of all members may be made without a serious burden, and (d) that the Examiner has not addressed MPEP 804.03, directed to nucleotide sequences, in which the Commissioner authorized a partial waiver of restriction practice, allowing the examination of up to ten sequences, and further traversing that the instant nucleic acids encode different fragments of the same protein, rather than different proteins. These arguments are not found persuasive because:

With respect to point (a) above, the Examiner explained clearly why the multitude of claimed sequence present a serious search burden in the presentation of the requirement in paper number 10, to wit: "the search for more than one product would be burdensome, because each is claimed not by nucleic acid sequence, but by the sequence of the protein encoded thereby, and requires a search of the corresponding region of SEQ ID NO: 1 as well as a 'reverse translation' search of the corresponding region of SEQ ID NO: 2, such that each individual sequence requires two sequence searches which are not required for any of the other sequences. Due to the use of 'comprising' language, it cannot even be said that the search for nucleic acids encoding amino acids 1-335 of SEQ ID NO: 2 would reveal art pertaining to, for instance a nucleic acid *comprising* a region encoding amino acids 5-17 of SEQ ID NO: 2, as the latter could be found embedded in a completely different protein."

With respect to point (b) above, the statutory basis for this requirement is U.S.C. 121. The Examiner regrets failing to make this clear in the previous Office Action.

With respect to point (c) above, that the current restriction represents a restriction within a Markush group, and that said Markush group has members that are sufficiently few in number and very closely related, so that a search of all members may be made without a serious burden, the Examiner notes MPEP 803.02, which states:

5 If the members of the Markush group are sufficiently few in number or so closely related that a search and examination of the entire claim can be made without serious burden, the examiner must examine all claims on the merits, even though they are directed to independent and distinct inventions. In such a case, the examiner will not follow the procedure described below and will not require restriction.

10 Since the decisions in *In re Weber*, 580 F.2d 455, 198 USPQ 328 (CCPA 1978) and *In re Haas*, 580 F.2d 461, 198 USPQ 334 (CCPA 1978), it is improper for the Office to refuse to examine that which applicants regard as their invention, unless the subject matter in a claim lacks unity of invention. In *re Harnish*, 631 F.2d 716, 206 USPQ 300 (CCPA 1980); and *Ex parte Hozumi*, 3 USPQ2d 1059 (Bd. Pat. App. & Int. 1984). Broadly, unity of invention exists where compounds included within a Markush group (1) share a common utility and (2) share a substantial structural feature disclosed as being essential to that utility.

20 In this case, the first requirement is not met, in that the members of the group are not sufficiently few in number or so closely related that a search and examination of the entire claim can be made without serious burden. Specifically, claim 67 alone encompasses 113,905 patentably distinct nucleic acids, some as short as 3 or 6 nucleotides' in length, which could, due to the use of 'open' language, be found embedded in any number of prior art nucleic acids. With respect to the search burden that this presents, see the discussion of point (a), above.

25 Further, contrary to the second paragraph quoted from the MPEP above, there is no unity of invention here, as no common utility has been presented, and there is no substantial structural feature disclosed as being essential to that utility; such would seem impossible, as the claimed fragments are, in many cases, non-overlapping, and thus do not share *any* structural feature.

30 Finally, with respect to applicant's point (d), that the Examiner has not addressed MPEP 804.03, directed to nucleotide sequences, in which the Commissioner authorized a partial waiver of restriction practice, allowing the examination of up to ten sequences, and further traversing that the

instant nucleic acids encode different fragments of the same protein, rather than different proteins. The Examiner notes that the correct MPEP citation is MPEP 803.04, not 804.03. The issue in question was a partial waiver of restriction practice to allow examination of up to ten sequences. This waiver was issued in 1996. Since then, the nucleic acid and protein databases that must be searched  
5 for each of the independent and distinct sequence claimed herein have multiplied many fold in size, such that it is now burdensome to search more than a single sequence in an application. Further, the waiver allowed, but did not require the Examiner to search ten sequences. With respect to applicants second point, it is not true that the claimed nucleic acids merely encode different fragments of the same protein, rather than different proteins. As many of the fragments are quite short, and could be  
10 embedded within other patentably distinct proteins, it cannot be said that they are merely fragments of a common protein, and a separate search is required for each possible fragment.

The requirement is still deemed proper and is therefore made FINAL.

The elected invention is nucleic acids which encode SEQ ID NO: 2, residues 1-335. Thus,  
15 claims 24, 25, 34-47, 51 and 55-66, as they are drawn to the elected invention, are under consideration. Claims 11, 13, 17, 18, 20, 22, 23, 26-33, 48-50, 52-54 and 67-105 are withdrawn from prosecution as being drawn to a non-elected invention.

**Formal Matters:**

20 ✓ The title of the invention is not descriptive. A new title is required that is clearly indicative of the invention to which the elected claims are directed.

✓ Claims 24, 25, 34-47, 51 and 55-66 are objected to for encompassing multiple patentably distinct inventions. The claims should be amended to include only the elected invention. Correction  
25 is required.

The information disclosure statements filed 1/25/01 and 8/15/01, papers 8 and 13 respectively,

have been considered. References AE-AI are not considered as they are merely sequences with no explanation of relevance or alignment with the disclosed sequences, such that relevancy to the claimed invention cannot be assessed.

5

**Objections and Rejections under 35 U.S.C. §§101 and 112:**

35 U.S.C. 101 reads as follows:

10

Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

Claims 24, 25, 34-47, 51 and 55-66 are rejected under 35 U.S.C. 101 because the claimed invention is not supported by either a specific, substantial and credible asserted utility or a well established utility.

15

20

25

The instant application discloses CTGF-4 and a nucleic acid which encodes such, SEQ ID NO: 1. The specification states at page 9 that the cDNA was isolated from a smooth muscle cDNA library, and is expressed at high levels in fetal liver, lymph node, kidney and ovary, and at lower levels in spleen, bone marrow, heart, placenta, lung, liver and prostate. At pages 9-10 there is a structural analysis of the putative protein, placing it in the CCN family of proteins, and stating that CTGF-4 “may be involved in the regulation of growth of cells comprising connective tissues.” The specification teaches at page 11 that probes to detect SEQ ID NO: 1 or a deposited clone may be used in “a variety of forensic and diagnostic methods”. At page 23 it is suggested that residues 241-335 of the sequence may, on the basis of similarity to HBGF, stimulate fibroblast DNA synthesis. At page 52, the specification proposes the use of the claimed nucleic acid in chromosome mapping, as antisense (for down regulating expression of CTGF-4), in RFLP or forensic analysis, in tissue typing, diagnostic methods, or gene therapy. The protein encoded thereby is stated to be useful in assays, or diagnostic or treatment methods (see page 65, for example).

None of the aforementioned uses is considered to be specific, substantial and credible, as set

forth in the Utility Examination Guidelines of 1/5/2001, Federal Register 66(4) beginning at page 1092. It is not predictable that CTGF-4 will share function with Heparin Binding Growth Factor. It is noted that a sequence search of SEQ ID NO: 2 did not yield a single match to HBGF. However, HBGF is a subfragment of CTGF, with which alignment was obtained. CTGF-4 is only 45% identical to CTGF, and, based upon a rough calculation, about 55% identical to the region corresponding to HBGF. One of skill in the art would not consider this level of identity to be predictive of function. The assertion that the disclosed CTGF-4 would have biological activities similar to known HBGF cannot be accepted in the absence of supporting evidence, because the relevant literature reports examples of polypeptide families wherein individual members have distinct, and sometimes even opposite, biological activities. For example, Tischer et al. (U.S. Patent 5,194,596) establishes that VEGF (a member of the PDGF, or platelet-derived growth factor, family) is mitogenic for vascular endothelial cells but not for vascular smooth muscle cells, which is opposite to the mitogenic activity of naturally occurring PDGF which is mitogenic for vascular smooth muscle cells but not for vascular endothelial cells (column 2, line 46 to column 3, line 2). The differences between PDGF and VEGF are also seen *in vivo*, wherein endothelial-pericyte associations in the eye are disrupted by intraocular administration of PDGF but accelerated by intraocular administration of VEGF (Benjamin et al., 1998, Development 125:1591-1598; see Abstract and pp. 1594-1596). Generally, the art acknowledges that function cannot be predicted based solely on structural similarity to a protein found in the sequence databases. For example, Skolnick et al. (2000, Trends in Biotech. 18:34-39) state that knowing the protein structure by itself is insufficient to annotate a number of functional classes, and is also insufficient for annotating the specific details of protein function (see Box 2, p. 36). Similarly, Bork (2000, Genome Research 10:398-400) states that the error rate of functional annotations in the sequence database is considerable, making it even more difficult to infer correct function from a structural comparison of a new sequence with a sequence database (see especially p. 399). Such concerns are also echoed by Doerks et al. (1998, Trends in Genetics 14:248-250) who state that (1) functional information is only partially annotated in the database, ignoring multi functionality, resulting in underpredictions of functionality of a new protein and (2) overpredictions

of functionality occur because structural similarity often does not necessarily coincide with functional similarity. Smith et al. (1997, Nature Biotechnology 15:1222-1223) remark that there are numerous cases in which proteins having very different functions share structural similarity due to evolution from a common ancestral gene. Accordingly, in view of the cited art, the skilled artisan would not accept, without experimental confirmation, that CTGF-4 would share the mitogenic activity for fibroblasts of HBGF based upon the sequence similarity between the two proteins.

With regard to the remaining uses asserted by applicants, the disclosed use for diagnosis of chromosomal disorders is not credible, in the absence of any disclosed chromosomal disorder, or any disease or condition which could be so diagnosed. Use for chromosomal mapping is not considered by the Patent Office to be a specific or substantial utility, as such use could be asserted for *any* cDNA. Use in RFLP or forensic analysis is similarly non-specific, as such use could be asserted for *any* cDNA. No assertion of diagnostic or therapeutic use of either the claimed nucleic acids nor the protein encoded thereby can be considered to be specific or substantial, much less credible, as there is no disclosure of any condition which can be so diagnosed or treated. Finally, the disclosure that the encoded protein “may be involved in the regulation of growth of cells comprising connective tissues” is merely an invitation to experiment, and would not be considered credible by one of skill in the art; mere homology and expression patterns is not accepted by those of skill in the art as being predictive of function. In *Brenner v. Manson*, 148 U.S.P.Q. 689 (Sup. Ct., 1966), a process of producing a novel compound that was structurally analogous to other compounds which were known to possess anti-cancer activity was alleged to be useful because the compound produced thereby was potentially useful as an anti-tumor agent in the absence of evidence supporting this utility. The court expressed the opinion that all chemical compounds are “useful” to the chemical arts when this term is given its broadest interpretation. However, the court held that this broad interpretation was not the intended definition of “useful” as it appears in 35 U.S.C. § 101, which requires that an invention must have either an immediately obvious or fully disclosed “real world” utility. The instant claims are drawn to a protein which has undetermined function or biological significance, and polynucleotides encoding such. Until some actual and specific activity can be attributed to the protein

identified in the specification as CTGF-4 protein or the polynucleotides encoding it, the claimed invention is incomplete.

5

The following is a quotation of the first paragraph of 35 U.S.C. 112:

10

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

15

Claims 24, 25, 34-47, 51 and 55-66 are also rejected under 35 U.S.C. 112, first paragraph. Specifically, since the claimed invention is not supported by either a specific, substantial and credible asserted utility or a well established utility for the reasons set forth above, one skilled in the art clearly would not know how to use the claimed invention.

20

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

25

Claims 34-36, 47, 51 and 55-57 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

X Claims 34-36 are indefinite for failing to indicate the relationship between the recited structural elements. Specifically, it is not clear how the "heterologous polynucleotide" of claim 34, for example, relates to the polynucleotide of claim 24. In claim 34, it is not clear whether the



X  
heterologous sequence is attached at an end or might be internally inserted. In claims 35 and 36, it is not clear whether applicants intend an operable attachment that would produce a fusion protein, or merely that the two recited portions be present on the same vector. Claims 55-57 are similarly indefinite.

5 ✓  
Claims 36 and 57 are further indefinite, as it is not clear to which immunoglobulin the claims refer. Amendment to insert the article "an" prior to 'immunoglobulin' would be remedial.

Xb! ✓  
Claim 47 is indefinite for reciting "further comprises". It would appear that applicants intend a molecule with at least two polynucleotides 90% or more identical to a second polynucleotide which encodes a recited portion of SEQ ID NO: 2, but that does not seem concordant with the disclosure, and it is not clear how those two sequences are related, that is, what relationship they bear to one another in the context of the claimed isolated nucleic acid molecule. Claim 51 is similarly indefinite.

**Prior Art:**

15  
The prior art made of record and not relied upon is considered pertinent to applicant's disclosure.

WO 99/21998, cited by applicants, discloses nucleic acids encoding WISP-1, which is 100% identical to SEQ ID NO: 2 of the current application.

20  
Pennica et al., PNAS 95:14717, December 1998, cited by applicants, also discloses WISP-1 and nucleic acids encoding such. The paper teaches that WISP-1 genomic DNA was amplified in colon cancer cell lines and in human colon tumors, and overexpressed 2- to over 30-fold in 84% of tumors examined compared with patient-matched normal mucosa (see abstract).

25  
Hashimoto et al., J. Exp. Med. 187:289-296, 2/2/98, cited by applicants, teaches the Elm-1 gene, which the protein encoded thereby being 86.5% identical to SEQ ID NO: 2.

Serial Number 09/325019

Art Unit 1647

---


**Advisory Information:**

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Lorraine M. Spector, whose telephone number is (703) 308-1793. Dr. Spector can normally be reached Monday through Friday, 9:00 A.M. to 5:30 P.M.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Gary Kunz, can be reached at (703)308-4623.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist at telephone number (703) 308-0196.

Certain papers related to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Examiner Spector via telephone number 703-746-5228. The faxing of such papers must conform with the notices published in the Official Gazette, 1156 OG 61 (November 16, 1993) and 1157 OG 94 (December 28, 1993) (see 37 C.F.R. § 1.6(d)). NOTE: If Applicant does submit a paper by fax, the original signed copy should be retained by applicant or applicant's representative. NO DUPLICATE COPIES SHOULD BE SUBMITTED so as to avoid the processing of duplicate papers in the Office.

  
Lorraine Spector, Ph.D.  
Primary Examiner

LMS  
09/325019.1  
11/4/01